Hyperbaric oxygen does not accelerate latent in vivo prostate cancer: implications for the treatment of radiation-induced haemorrhagic cystitis.
Auteur(s)
KIAN TAI CHONG, NEIL B. HAMPSON, DAVID G. BOSTWICK, ROBERT L. VESSELLA, JOHN M. CORMAN
Jaartal
2004
Tijdschrift
BJU INTERNATIONAL 94, 1275–1278
Type publicatie
Onderzoek
Onderzoek
Proefdieronderzoek,
Aantal
60 naakt muizen
Selectiecriteria
NVT
Methode
Human prostate LNCaP cells were injected
into 60 severe combined-immunodeficient
mice; of these 24 (40%) did not develop
palpable tumours after 6 weeks. They were
randomized to undergo 20 sessions of either
HBO2 or normobaric air in standardized
conditions, and observed for another 4 weeks before the histological assessment of any
palpable tumours that developed. Analysis of
developed LNCaP tumours included tumour
volume, microvessel density, MIB-1, p53, p27
and racemase staining intensity.
into 60 severe combined-immunodeficient
mice; of these 24 (40%) did not develop
palpable tumours after 6 weeks. They were
randomized to undergo 20 sessions of either
HBO2 or normobaric air in standardized
conditions, and observed for another 4 weeks before the histological assessment of any
palpable tumours that developed. Analysis of
developed LNCaP tumours included tumour
volume, microvessel density, MIB-1, p53, p27
and racemase staining intensity.
Resultaat
HBO2 was associated with less prostate
tumour progression than normobaric air
(P = 0.26). During HBO2 therapy, 10 mice
remained free of palpable tumours, compared
with seven controls (P = 0.30). On evaluation
during the 4 weeks after therapy, six mice
treated with HBO2 remained free of palpable
tumours, vs eight of the controls (P = 0.17).
There was tumour invasion and necrosis in a
two of six and four of the HBO2 group during
and after therapy, respectively, vs five and seven of the controls. Tumour microvessel
density, proliferative index, differentiation
and apoptosis markers were similar in both
groups.
tumour progression than normobaric air
(P = 0.26). During HBO2 therapy, 10 mice
remained free of palpable tumours, compared
with seven controls (P = 0.30). On evaluation
during the 4 weeks after therapy, six mice
treated with HBO2 remained free of palpable
tumours, vs eight of the controls (P = 0.17).
There was tumour invasion and necrosis in a
two of six and four of the HBO2 group during
and after therapy, respectively, vs five and seven of the controls. Tumour microvessel
density, proliferative index, differentiation
and apoptosis markers were similar in both
groups.
Conclusie
HBO2 does not accelerate the growth of
indolent prostate cancer in a murine model,
suggesting that it does not increase the risk
of residual prostate cancer reactivation when
it is used to manage radiation-induced
haemorrhagic cystitis in patients treated by
pelvic radiotherapy for prostate cancer.
indolent prostate cancer in a murine model,
suggesting that it does not increase the risk
of residual prostate cancer reactivation when
it is used to manage radiation-induced
haemorrhagic cystitis in patients treated by
pelvic radiotherapy for prostate cancer.
Externe link
Link naar abstract op Online Wiley
Indicatie
LRTI blaas
